Improving health R & D financing for developing countries: A menu of innovative policy options

Health Affairs

Volumn 28, Issue 4, 2009, Pages 974-985

  Hecht, Robert ^a   Wilson, Paul ^b   Palriwala, Amrita ^a  

^a RESULTS FOR DEVELOPMENT INSTITUTE   (United States)

^b Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MALARIA VACCINE; VACCINE;

DRUG COST; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; HEALTH CARE FINANCING; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HUMAN; MALARIA; MEDICAL TECHNOLOGY; REVIEW; VACCINATION;

DEVELOPING COUNTRIES; DRUG INDUSTRY; NEEDS ASSESSMENT; POLICY MAKING; RESEARCH;

EID: 67651236334     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.28.4.974     Document Type: Review

References (33)

1. N. Maire et al., "Predictions of the Epidemiologic Impact of Introducing a Pre-Erythrocytic Vaccine into the Expanded Program on Immunization in Sub-Saharan Africa," American Journal of Tropical Medicine and Hygiene 75, no. 2 Supp. (2006): 111-118.
2. D.S. Shepard et al., "Cost-Effectiveness of a Pediatric Dengue Vaccine," Vaccine 22, nos. 9-10 (2004): 1275-1280.
3. J. Stover et al., "The Impact of an AIDS Vaccine in Developing Countries: A New Model and Initial Results," Health Affairs 26, no. 4 (2007): 1147-1158.
4. World Health Organization, Diarrhoeal Diseases, February 2009, http://www.who.int/vaccine-research/diseases/diarrhoeal/en/index.html (accessed 14 April 2009).
5. Commission on Health Research for Development, Health Research: Essential Link to Equity in Development (New York: Oxford University Press, 1990).
6. WHO Expert Working Group on R&D Financing, http://www.who.int/phi/ 1stmeeting/en/index.html (accessed 4 March 2009);
7. and WHO, Global Strategy and Plan of Action on Public Health, Innovation, and Intellectual Property, Sixty-First World Health Assembly, 24 May 2008, http://www.who.int/gb/ebwha/pdf-files/A61/A61-R21-en.pdf (accessed 4 March 2009).
8. P. Wilson, S. Post, and S. Srinivas, "R&D Models: Lessons from Vaccine History," Policy Research Working Paper no. 14, June 2007, http://www.iavi.org/viewfile.cfm?fid=45872 (accessed 12 January 2009).
9. Dalberg Global Development Advisors, "Initiative for Sustainable Funding for R&D for Neglected Diseases," 8 November 2007, http://www.ifpma.org/pdf/2007-11-08-Soren-Peter-Andreasen.pdf (accessed 6 January 2009).
10. Stop TB, "Strategic Plan of the Stop TB Partnership Working Group on New TB Vaccines, 2006-2015," http://www.stoptb.org/wg/new-vaccines/assets/ documents/Strat%20Plan%20New%20Vaccines.pdf (accessed 4 March 2009).
11. P.A. Wilson and R. Hecht, "Financing of Vaccine R&D-Gaps and Opportunities," Global Forum Update on Research for Health 4 (2007): 88-93.
12. A. Gawrylewski, "Tackling Peer Review Bias," TheScientist.com, 28 July 2008, http://www.the-scientist.com/blog/display/54893 (accessed 14 April 2009).
13. London School of Economics and Political Science, The New Landscape of Neglected Disease Drug Development (London: Wellcome Trust, September 2005).
14. George Institute for International Health, Neglected Disease Research and Development: How Much Are We Really Spending? February 2009, http://www.thegeorgeinstitute.org/shadomx/apps/fms/fmsdownload.cfm?file-uuid= 409D1EFD-BF15-8C94-E71C-288DE35DD0B2&siteName=iih (accessed 4 March 2009).
15. Based on NIH data analyzed by Kevin Fisher, AIDS Vaccine Advocacy Coalition, personal communication, September 2008.
16. S.E. Frew, H.E. Kettler, and P.A. Singer, "The Indian and Chinese Health Biotechnology Industries: Potential Champions of Global Health?" Health Affairs 27, no. 4 (2008): 1029-1041.
17. Brookings Institution, "Advance Market Commitments for Vaccines," 2008, http://www.brookings.edu/projects/global-health/~/media/ Files/Projects/globalhealth/healthsnapshots/vaccines.pdf (accessed 6 January 2009);
18. and O. Barder, M. Kremer, and R. Levine, Making Markets for Vaccines: Ideas to Action, 2005, http://www.cgdev.org/doc/books/vaccine/MakingMarkets- complete.pdf (accessed 12 January 2006).
19. Because these vaccines are already in very late-stage development, the main aim of the pneumo AMC will be to ensure adequate supply to developing countries at an affordable price.
20. GAVI Alliance, "Saving Lives with New Vaccines: Advanced Market Commitments," 2007, http://www.vaccineamc.org/files/AMC-FactSheet-v2.pdf (accessed 6 January 2009).
21. World Bank and GAVI Alliance, Framework Document: Pilot AMC for Pneumococcal Vaccines, 9 November 2006, http://www.vaccineamc.org/files/ Framework%20Pneumo%20AMC%20Pilot.pdf (accessed 14 April 2009).
22. BIO Ventures for Global Health, "About PRVs," 2008, http://prvinfo.org/about (accessed 14 April 2009);
23. and IAVI, "U.S. FDA Priority Review Vouchers: An Effective Incentive to Develop Drugs and Vaccines for Neglected Diseases?" 2008, https://www.iavi.org/viewfile.cfm?fid=47963 (accessed 6 January 2009).
24. U.S. Food and Drug Administration, "FDA Approves Coartem Tablets to Treat Malaria," 8 April 2009, http://www.fda.gov/bbs/topics/NEWS/2009/ NEW01989.html (accessed 7 May 2009).
25. Brookings Institution, "International Finance Facility for Immunization," 2008, http://www.brookings.edu/projects/global-health/~/ media/Files/Projects/globalhealth/healthsnapshots/iffim.pdf (accessed 6 January 2009).
26. IAVI, "IAVI's Innovation Fund to Bring Novel Early-Stage Technologies to AIDS Vaccine Research," 2007, http://www.iavi.org/viewfile. cfm?fid=46894 (accessed 6 January 2009).
27. Bill and Melinda Gates Foundation, "Gates Foundation Invests in 104 Novel Ideas for Global Health," Press Release, 22 October 2008, http://www.grandchallenges.org/about/Newsroom/Pages/GCERound1Grants.aspx (accessed 6 January 2009).
28. J. Love, "The Role of Prizes in Developing Low-Cost, Point-of-Care Rapid Diagnostic Tests and Better Drugs for Tuberculosis," Medicins sans Frontiers Expert Meeting, 11 April 2008, Geneva, Switzerland, http://www.keionline.org/misc-docs/Prizes/prize-tb-msf-expert-meeting.pdf (accessed 14 April 2009).
29. J. Love and T. Hubbard, "The Big Idea: Prizes to Stimulate R&D for New Medicines," Chicago-Kent Law Review 82, no. 3 (2007): 1519-1554;
30. and A. Hollis and T. Pogge, The Health Impact Fund: Making New Medicines Accessible for All, 2008, http://www.yale.edu/macmillan/igh/hif- book.pdf (accessed 12May 2009).
31. D. de Ferranti et al., "Innovative Financing for Global Health: Tools for Analyzing the Options," August 2008, http://www.brookings.edu/ papers/2008/08-global-health-de-ferranti.aspx (accessed 14 April 2009).
32. There has also been a recent attempt to examine the range of possible innovative development financing mechanisms by the Leading Group on Solidarity Levies. See "Invitation: The Second Plenary Meeting of the Leading Group," 18 December 2006, http://www.innovativefinance-oslo.no/hjem.cfm (accessed 14 April 2009).
33. See, for example, OECD Global Forum on Development, "Innovative Financing in Health," 7 October 2008, http://www.oecd.org/document/12/0, 3343,en-21571361-37824719-41467532-1-1-1-1,00.html (accessed 12 May 2009).